Biopharma giant Johnson & Johnson’s ($JNJ) stock hit new highs this year after reporting its Q2 results on July 16th, giving ...

Johnson & Johnson's stock offers value with promising MedTech growth, raised guidance, strong dividends, and bullish ...

The big appeal of Johnson & Johnson over the years has been that it's a relatively safe stock to own, and it also offers an attractive dividend yield of 2.8% -- the S&P 500 average is just over 1.5%.

Johnson & Johnson announced Friday it will split itself into two publicly traded companies, separating its lucrative pharmaceutical and medical devices divisions from the consumer products ...

This 12% rise for JNJ stock since late 2019 can primarily be attributed to 1.Johnson & Johnson’s revenue growth of 16% to $95 billion over the last twelve months, compared to $82 billion in 2019 ...

Johnson & Johnson’s Covid-19 single-shot vaccine was shown to be 66% effective in preventing moderate and severe disease in a global Phase 3 trial, but 85% effective against severe disease, the ...

Johnson & Johnson plans to spin off its consumer health division that sells Listerine and Baby Powder to focus on pharmaceuticals and medical devices in the biggest shake-up in the U.S. company's ...

Johnson & Johnson spun off liabilities — including roughly 38,000 lawsuits — linked to claims of asbestos contamination in its baby powder to a new firm, which then declared bankruptcy.